NASDAQ · ARTLW
Artelo Biosciences, Inc.
Healthcare · Biotechnology
$0.01
Up+$0.00 (+0.00%)
Updated Aug 15, 2026, 4:01 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 13.07K
- P/E ratio
- -0.1
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 29.4K
- Avg. volume
- 0
Price performance
ARTLW price history
1M range · 0 trading sessions · Daily adjusted prices
ARTLW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest ARTLW news
The latest Smart Investors Daily articles mentioning ARTLW.
Stock researchCompany · Overview
ARTLW research
Overview
Company profile and research snapshot.
Company profile
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
